Phase 2 Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People whose best vision with glasses or contact lenses is at least 20/40
- People whose eye pressure measured at 24 mmHg or below at both the screening and baseline appointments
- People who have shown progressive thinning of certain layers at the back of the eye (RNFL and/or GCIPL), detected by specialised eye scans, over the past 3 years in at least one eye
Who may not be able to join:
- People who have diabetes, kidney disease, or liver disease
- People with an abnormally high level of short-sightedness, known as pathological myopia
- People with cognitive conditions such as Alzheimer's disease or similar impairments
- People who have conditions other than glaucoma that may cause vision loss or changes to the appearance of the optic nerve
- People who are unable to complete reliable visual field tests (a type of eye assessment)
- People whose eye scan (OCT) images are not of sufficient quality for analysis
Please note: Both eyes may be included in the study if both meet the eligibility criteria, as determined by the trial site.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christopher LEUNG, MD, The University of Hong Kong
Phone: (852)3962-1405
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rates of RNFL/GCIPL thinning (Evaluation of Neuroprotection); Change in visual field sensitivity (Evaluation of Neuroenhancement)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.